Several investigators have addressed the role of ibrutinib in the treatment of PCNSL patients, considering that ibrutinib is a small molecule that rapidly penetrates the blood–brain barrier (BBB), and, as mentioned earlier, PCNSL is enriched by ABC subtype and mutations of CD79B and MYD88. This evidence concerns the gene MYD88 and primary central nervous system lymphoma.